Theralase Technologies Inc. (TLTFF)
OTC Markets OTCQB
Fundamentals
Valuation and ratings
Theralase Technologies Inc. trades at USD0.19. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
The full research page for TLTFF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.